BridgeBio Pharma, Inc. (BBIO)
CIK 1743881 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 195.5M shares as of Aug 3, 2026 (10-Q).
Cash runway
Funded — but tight
~18 months of cash · watch
Full breakdown: cash runway tool · source filing →
Warrants
No warrant figures tagged in this filer’s XBRL facts. That means the company has not reported them in structured form; it does not prove no warrants exist. The exhibits are the ground truth.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| 2029 Convertible Senior Notes | $747.5M | $747.5M | $97.04 | 2.25% | ~7.7M sh |
| 2033 Convertible Senior Notes | $632.5M | $632.5M | $110.58 | 0.75% | ~5.7M sh |
| 2031 Convertible Senior Notes | $575.0M | $575.0M | $49.81 | 1.75% | ~11.5M sh |
| 2027 Convertible Senior Notes | $550.0M | $550.0M | $42.71 | 2.5% | ~12.9M sh |
If every note above converted at its tagged price: ~37.8M new shares on 195.5M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 10, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 195.5M | Aug 3, 2026 |
| + 2029 Convertible Senior Notes (if fully converted) | 7.7M | Jun 30, 2026 |
| + 2033 Convertible Senior Notes (if fully converted) | 5.7M | Jun 30, 2026 |
| + 2031 Convertible Senior Notes (if fully converted) | 11.5M | Jun 30, 2026 |
| + 2027 Convertible Senior Notes (if fully converted) | 12.9M | Jun 30, 2026 |
| Fully diluted estimate | 233.3M | +19.4% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $2489.2Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 2 executed · 2 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full BBIO workspace